Loading
companiesCompany
RA Capital Management
A Boston investment firm that funds biotech companies both privately and on the stock market, and incubates its own. Its cancer bets include Aktis Oncology, CG Oncology and Bicara Therapeutics.
Overview
RA Capital Management was founded in January 2002 by Richard Aldrich and Peter Kolchinsky and is based in Boston (Wikipedia). It runs an evergreen fund that invests across private and public companies, dedicated venture funds (Nexus), a company-creation incubator called Raven, a clinical development accelerator (Blackbird) and an internal research group, TechAtlas. The firm is a frequent lead in crossover rounds ahead of IPOs. Its portfolio page lists a long run of oncology names: Acrivon Therapeutics, Aktis Oncology (alpha radiopharmaceuticals), Alpha-9 Oncology, Bicara Therapeutics, Black Diamond Therapeutics, Boundless Bio, CG Oncology (oncolytic immunotherapy for bladder cancer), Olema Oncology, PMV Pharma (p53) and Pyxis Oncology.
Portfolio (10)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Adcendo Copenhagen, DK | Growth stage | biotech | Sarcomas (soft tissue, bone, GIST) | Series C 2026, $75M |
| Adela Toronto, CA | Startup | diagnostics | Series A 2023, $48M | |
| Alentis Therapeutics Basel, CH | Growth stage | biotech | Series D 2024, $181M | |
| Alpha-9 Oncology Vancouver, CA | Growth stage | radiopharma | Melanoma | Series C 2024, $175M |
| Enliven Therapeutics Boulder, CO, US | Public | biotech | Non-small-cell lung cancer | Crossover 2023, $165M |
| Mariana Oncology Watertown, MA, US | Acquired | radiopharma | Small-cell lung cancer | Acquisition 2024, $1B |
| Nucleix Rehovot, IL | Growth stage | diagnostics | Bladder & urothelial cancerNon-small-cell lung cancer | Series C 2021, $55M |
| Obsidian Therapeutics Cambridge, MA, US | Public | cell therapy | MelanomaNon-small-cell lung cancer | Crossover 2026, $350M |
| Tango Therapeutics Boston, MA, US | Public | biotech | Pancreatic ductal adenocarcinomaNon-small-cell lung cancerGlioma & glioblastoma | IPO 2021, $353M |
| Triana Biomedicines Lexington, MA, US | Startup | biotech | Non-small-cell lung cancerHR-positive / HER2-negative breast cancer | Series B 2025, $120M |
Similar pages
- CompanyLogos Capital
Shares Obsidian Therapeutics, Triana Biomedicines, Adcendo, Tango Therapeutics and the tag vc.
- CompanyNovo Holdings
Shares Alentis Therapeutics, Obsidian Therapeutics, Adcendo and the tag vc.
- CompanyOrbiMed
Shares Adela, Alentis Therapeutics, Adcendo and the tag vc.
- CompanyAtlas Venture
Shares Mariana Oncology, Obsidian Therapeutics, Triana Biomedicines and the tag vc.
- CompanyFrazier Life Sciences
Shares Enliven Therapeutics, Alentis Therapeutics, Alpha-9 Oncology and the tag vc.
- CompanyVenrock
Shares Enliven Therapeutics, Adcendo and the tag vc.
- CompanyTCGX (TCG Crossover)
Shares Obsidian Therapeutics, Adcendo and the tag vc.
- CompanyLightspeed Venture Partners
Shares Alpha-9 Oncology, Triana Biomedicines and the tag vc.